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INTRODUCTION 
Pancreatic polypeptide (PP) and peptide YY (PYY) belong
to the neuropeptide Y (NPY) family, which have well-con-
served amino acid sequences (1) containing numerous tyrosines
and tertiary structures (2, 3) with wide variation in anatom-
ical distribution (4). The structural similarity between these
peptides leads to the hypothesis that they are homologous,
belonging to a family that has been termed the NPY family
on the basis that NPY is evolutionarily the most ancient
member. Five receptors for NPY family have so far been
cloned, Y1, Y2, Y4, Y5, and y6, and found to belong to the
huge family of heptahelical G protein-coupled receptors (5).
Y4 receptor mRNA has been detected in the heart, gut,
adrenal gland and artery (6-8). PP has a high affinity for Y4
receptor whereas PYY and NPY have a low affinity for the
Y4 receptor (9, 10). PYY is as potent as NPY in activating
Y1, Y2, and Y5 receptors. 
Among these peptides, PP expression is restricted to pan-
creatic endocrine cells, type F islet cells, in which PP is releas-
ed into the circulation after ingestion of food to regulate pan-
creatic and gastric secretion, as well as gallbladder contrac-
tion (11). PYY is also expressed in both neurons of gastroin-
testinal tracts and endocrine cells, where it has an inhibitory
effect on gastric motility and secretion (4). NPY is co-local-
ized with noradrenaline in most sympathetic nerve fibers
throughout the body (12). Several studies about cardiovas-
cular functions of NPY family have been performed. Rat PP
inhibits neurogenic vasoconstriction evoked by electrical stim-
ulation through Y4 receptor (4). In the mouse, NPY activates
Y2 receptor on the parasympathetic nerve terminal (13) and
evokes potent vasoconstriction by activating Y1 receptors. A
recent study (14) showing slow heart rate and low mean arteri-
al pressure as a result of reduced sympathetic activity in Y4
receptor-knockout mice suggests that Y4receptor deletion dis-
rupts autonomic balance within the cardiovascular system.
Only a few reports about the effects of PP on cardiovascular
function are available (14, 15). Therefore, the aim of the pre-
sent study was to investigate the direct effects of PP on atrial
dynamics and atrial natriuretic peptide (ANP) release and to
identify its receptor subtypes using isolated perfused rat atria.
MATERIALS AND METHODS 
Animals
Sprague-Dawley rats, weighing 300-350 g, were obtained
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Different Regulation of Atrial ANP Release through Neuropeptide 
Y2 and Y4 Receptors 
Neuropeptide Y (NPY) receptors are present in cardiac membranes. However, its
physiological roles in the heart are not clear. The aim of this study was to define the
direct effects of pancreatic polypeptide (PP) on atrial dynamics and atrial natriuretic
peptide (ANP) release in perfused beating atria. Pancreatic polypeptides, a NPY
Y4 receptor agonist, decreased atrial contractility but was not dose-dependent. The
ANP release was stimulated by PP in a dose-dependent manner. GR 23118, a NPY
Y4 receptor agonist, also increased the ANP release and the potency was greater
than PP. In contrast, peptide YY (3-36) (PYY), an NPY Y2 receptor agonist, suppress-
ed the release of ANP with positive inotropy. NPY, an agonist for Y1, 2, 5 receptor, did
not cause any significant changes. The pretreatment of NPY (18-36), an antago-
nist for NPY Y3 receptor, markedly attenuated the stimulation of ANP release by
PP but did not affect the suppression of ANP release by PYY. BIIE0246, an antag-
onist for NPY Y2 receptor, attenuated the suppression of ANP release by PYY. The
responsiveness of atrial contractility to PP or PYY was not affected by either of the
antagonists. These results suggest that NPY Y4 and Y2 receptor differently regu-
late the release of atrial ANP. 
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tractility
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throughout the experiments in a laminar flow cabinet, and
were maintained on standard laboratory chow ad libitum. All
experimental animals used in this study were performed under
a protocol approved by the Institutional Animal Care and
Use Committee of the Chonbuk National University. Stan-
dard guidelines for laboratory animal care were followed.
Experimental procedures
Isolated perfused beating atria were prepared using a pre-
viously described method (16). In brief, the left atrium was
dissected from the heart after killing and fixed into a Tygon
cannula. The cannulated atrium was transferred into an organ
chamber, immediately perfused with oxygenated HEPES
buffer solution at 36.5℃, and paced at 1.3 Hz (duration 0.3
msec, voltage 40 V). The composition of the HEPES buffer
solution was as follows (HEPES 10 mM, NaCl 118 mM,
KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, NaHCO3
25 mM, glucose 10 mM, and bovine serum albumin 0.1%,
pH 7.4). The pericardial buffer solution contained (3H) inulin
to measure the translocation of extracellular fluid (ECF). Intra-
atrial pressure was recorded on a Physiograph (MK-IV, Narco
Bio-systems INC., Houston, TX, U.S.A.) via a pressure trans-
ducer (Statham P23Db, Oxnard, CA, U.S.A.) and pulse pres-
sure was calculated from the differences in systolic and dias-
tolic intra-atrial pressures. After stabilization for 100 min,
the perfusate was collected at 2-min intervals under 4℃. 
Experiments were performed with four groups. Group 1
was atrium perfused with HEPES buffer (n=6) throughout
the experiment. After stabilization, the perfusate was collect-
ed at 2-min intervals for 70 min. Group 2 was atrium per-
fused with human PP (10-8M, n=6; 10-7M, n=8; 3×10-7M,
n=7). PP, a NPY Y4 receptor agonist, was introduced into
the atrial lumen after a 10-min control period, and perfusate
was collected for 60 min. Group 3 was atrium perfused with
GR 23118 (NPY Y1 receptor antagonist and Y4 receptor
agonist, 10-7M, n=6), PYY (3-36) (NPY Y2 receptor ago-
nist, 10-7M, n=7) or rat NPY (NPY Y1,2,5 receptor agonist,
10-7M, n=8). GR 23118, PYY or NPY was introduced into
the atrial lumen after a 10-min control period, and perfusate
was collected for 60 min. 
Group 4 was atrium pretreated with an antagonist for Y3
or Y2 receptor. NPY (18-36) (3×10-7M, n=7), an antago-
nist for NPY Y3 receptor, or BIIE0246 (3×10-7M, n=7), an
antagonist for NPY Y2 receptor was administered as a pre-
treatment at 20 min after the start of the perfusion. PP (10-7
M, n=7) or PYY (3-36) (10-7M, n=7) was simultaneously
infused with an inhibitor after a 10-min control period. 
Measurement of ANP concentration
The concentrations of immunoreactive ANP in the per-
fusate were measured with a specific radioimmunoassay
(RIA), as described previously (17). RIA was performed in
Tris-acetate buffer (0.1 M, pH 7.4) containing neomycin
(0.2%), ethylenediamine tetra-acetic acid (1 mM), soybean
trypsin inhibitor (50 benzoyl arginine ethyl ester units/mL),
aprotinin (200 kallikrein inhibiting unit/mL), phenylmethyl-
sulfonyl fluoride (0.4 mg%), sodium azide (0.02%) and bovine
serum albumin (1%). Standard and samples were incubated
with anti-ANP antibody and (125I) ANP for 24 hr at 4℃.
Bound forms were separated from the free form using a char-
coal suspension or second antibody. RIA for ANP was done
on the day of experiments and all samples in an experiment
were analyzed in a single assay. 
We previously reported a two-step sequential mechanism
of ANP secretion from the atrium (18, 19): first, atrial release
of ANP into the interstitial space occurs by means of atrial
stretching, and second, the released ANP is translocated into
the atrial lumen, concomitantly with ECF translocation due
to contraction. Therefore, the interstitial ANP concentra-
tion was calculated using the ANP secretion divided by extra-
cellular fluid (ECF) translocation and 3060 (molecular mass
for ANP-[1-28]) and was expressed in μ M (18, 19). 
Measurement of ECF translocation
The radioactivity of (3H) inulin in the atrial perfusate was
measured with a liquid scintillation counter (Tris-Carb 23-
TR; A Packard Bioscience Company, Downers Grove, IL,
U.S.A.). The amount of ECF translocated through the atrial
wall was calculated from the total radioactivity in the per-
fusate divid- ed by the radioactivity in the pericardial reser-
voir and atrial wet weight and was expressed in μ L/min/g. 
Statistical analysis
The results are presented as the means±S.E.M. The sta-
tistical significance of the differences was assessed using anal-
ysis of variance followed by Duncan multiple range test. The
critical level of significance was set at p<0.05.
RESULTS
Effects of PP on atrial contractility and ANP release
After stabilization for 100 min, the perfusate was collect-
ed five times every 2 min to serve as a control period and
then PP was infused at a concentration of 10-8, 10-7, or 3×
10-7M. Fig. 1A shows the effects of PP on contractility, ECF
translocation, ANP secretion, and ANP concentration with
time. PP decreased atrial contractility (Fig. 1Aa). The secre-
tion of ANP gradually increased in a dose-dependent man-
ner (Fig. 1Ac) throughout the experiment without a change
in ECF translocation (Fig. 1Ab). We have previously report-
ed that the ANP released from atrial myocytes into the inter-
1028 F.L. Piao, K. Yuan, G.Y. Bai, et al.stitial space is translocated into the atrial lumen, concomi-
tantly with ECF translocation (18, 19). The translocation of
ECF is dependent on atrial contractility in this model. There-
fore, the ANP secretion in terms of ECF translocation, which
means the interstitial ANP concentration (Fig. 1Ad), was
significantly increased by PP. 
Fig. 1B shows the relative percent changes in pulse pres-
sure, ECF translocation, ANP secretion and concentration
obtained from the mean of five control values and the five
peak experimental values (50-60 min after drug infusion)
for exposure to the different doses of PP. PP decreased atrial
contractility without dose-dependency (Fig. 1Ba) but ECF
translocation did not change (Fig. 1Bb). The ANP secretion
was increased by 16.52±7.29, 35.35±10.13, and 48.22±
10.42% by 10-8, 10-7, or 3×10-7M PP, respectively, which
was dose-dependent (Fig. 1Bc). 
Effects of GR 23118, PYY (3-36) and NPY on atrial 
contractility and ANP release
To compare the intra-atrial effects of GR 23118 (Y1 antag-
onist and Y4 agonist), PYY (3-36) (Y2 agonist) and NPY
(Y1,2,5 agonist) with PP (Y4 agonist), GR 23118, PYY (3-
36) or NPY, at a concentration of 10-7M, was perfused into
atrial lumen. GR 23118 caused a gradual increase in ANP
release and decreases in atrial contractility and ECF translo-
cation (Fig. 2A). In contrast, PYY (3-36) abruptly decreased
the ANP secretion and concentration, which maintained
throughout the experiment. Atrial contractility and ECF
translocation significantly increased (Fig. 2Aa, Ab). NPY
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Fig. 1. (A) Effects of pancreatic polypeptide (10
-8M, n=6; 10
-7M, n=8; 3×10
-7M, n=7) on pulse pressure, ECF translocation, ANP secretion,
and ANP concentration in isolated perfused beating rat atria. Pancreatic polypeptide decreased atrial contractility without change in ECF
translocation. The ANP secretion and concentration gradually increased in terms of time. (B) Relative percent changes in pulse pressure,
ECF translocation, ANP secretion, and ANP concentration by pancreatic polypeptide. Values were expressed as percent changes of the
five peak experimental values for exposure to pancreatic polypeptide, as compared to the mean of the five control values. Pancreatic polypep-
tide increased the ANP secretion in a dose-dependent manner. Arrow indicates the start time of peptide infusion. PP, pancreatic polypep-
tide; CONT, control group; ECF transloc, ECF translocation; ANP conc, ANP concentration. *p<0.05; 
� p<0.01 vs. corresponding dose.
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NPY Receptor-Mediated ANP Release 1029slightly decreased the ANP secretion until 30 min without
significance (Fig. 2Ac). Atrial contractility and ECF translo-
cation also did not change significantly. 
Fig. 2B shows the comparison of relative percent changes
in several parameters by GR 23118, PYY (3-36) and NPY
with PP. GR23118-stimulated ANP secretion was greater
than PP. The suppression of ANP secretion by NPY and
PYY was significantly different from that by PP. 
Modification of intra-atrial effects of PP and PYY (3-36)
by receptor antagonists
To determine which Y receptor subtype(s) is(are) involved
in PP-induced ANP secretion, NPY (18-36), Y3 receptor
antagonist, or BIIE0246, Y2 receptor antagonist, was pre-
treated and PP or PYY (3-36) was simultaneously perfused.
PP-induced negative inotropy was not affected by the pre-
treatment of NPY (18-36) or BIIE0246 (Fig. 3A). However,
PP-stimulated ANP secretion was markedly attenuated by
NPY (18-36) (Fig. 3C, D) but was not affected by BIIE0246.
Both positive inotropy and suppression of ANP secretion
by PYY (3-36) were not affected by NPY (18-36). PYY (3-
36) -induced suppression of ANP secretion was attenuated
by BIIE0246, an antagonist for Y2 receptor. 
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Fig. 2. (A) Effects of pancreatic polypeptide (PP, 10
-7M, n=8), GR 23118 (10
-7M, n=6), neuropeptide Y (NPY, 10
-7M, n=8), and peptide YY
(3-36) (PYY, 10
-7M, n=7) on pulse pressure, ECF translocation, ANP secretion, and ANP concentration in isolated perfused beating rat atria.
GR 23118 decreased atrial contractility and ECF translocation, and increased the ANP secretion. In contrast, peptide YY (3-36) increased
atrial contractility and ECF translocation. The ANP secretion and concentration gradually decreased in terms of time. Neuropeptide Y also
decreased the ANP secretion without significant changes in atrial contractility and ECF translocation. (B) Comparison of relative percent
changes in several parameters between GR 23118, neuropeptide, peptide YY (3-36) and pancreatic polypeptide. Values were expressed
as percent changes of the three peak experimental values for exposure to neuropeptide family, as compared to mean of the five control
values. There was a significant difference in changes in ANP secretion by GR 23118, neuropeptide Y, and peptide YY (3-36), as com-
pared to pancreatic polypeptide. Legends are the same as in Fig. 1. *p<0.05; 
� p<0.01 vs. pancreatic polypeptide-exposed group. 
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In the present study, we found that PP and GR 23118 (Y4
receptor agonists) increased ANP secretion and PYY (3-36)
(NPY Y2 agonist) decreased ANP secretion. Therefore, we
suggest that NPY receptors differently regulate the release
of ANP. 
PP, mainly produced in the gut, retains up to 50% residue
identity to NPY or PYY, and a strong similarity in the C-
terminal secretion. PP binds rat and mouse Y4 receptor with
very high affinity (7, 20), which is expressed in the periph-
ery (21), including adrenal gland, gut, kidney (22) and heart.
Although many studies on gastric actions of PP have been
reported such as stimulation of gastric emptying, secretion
and motility (23), a few report on cardiovascular function of
PP are present (14, 15). In the present study, we investigat-
ed the intra-atrial direct effects of PP and PYY using isolat-
ed perfused rat atria. PP caused an increase in ANP secre-
tion and negative inotropy. In contrast, PYY (3-36) caused
a decrease in ANP secretion. It has been reported that PP
has a high affinity for Y4 receptor (24) and PYY (3-36) for
Y2 receptor (9). In the heart, Y2 and Y4 receptors have been
shown to have an important role on cardiovascular functions.
Rat PP inhibits neurogenic vasoconstriction evoked by elec-
trical stimulation through Y4 receptor (21) and transgenic
Y4-knockout mice show the significant impairment of car-
diovascular function (14). We wanted to define which NPY
receptor subtypes are involved in the regulation of ANP secre-
tion and atrial contractility by PP and PYY (3-36). Howev-
er, a specific Y4 receptor antagonist is not available. There-
fore, specific antagonists for Y2 and Y3 receptor subtypes were
used. The PP-induced stimulation of ANP secretion was
attenuated by Y3 receptor antagonist but not by Y2 receptor
antagonist. PYY (3-36)-induced suppression of ANP secre-
tion was attenuated by Y2 receptor antagonist but not by Y3
receptor antagonist. These results show a possible involve-
ment of the Y3 receptor for PP-induced ANP secretion. How-
ever, the Y3 receptor to this day is unproven, and even scien-
tists who originated the Y3 concept have confirmed nega-
tive findings (especially with the CXCR4 chemokine recep-
tor) related to the concept (25). It has also been reported that
NPY (18-36) may act as an antagonist for Y4 receptors (26).
Additionally, GR23118, a specific Y4 receptor agonist and
Y1 antagonist, stimulated the ANF secretion more than PP.
Therefore, we suggest that NPY Y2 and Y4 receptors may
differently regulate the release of atrial ANP. 
In this study, PP caused negative inotropy and PYY (3-
36) caused positive inotropy. This response was relatively
small. Neither Y2 nor Y3 receptor antagonists modified the
inotropic effects of PP and PYY (3-36). It is not clear that
the hemodynamic changes by PP and PYY (3-36) are their
own effects because of the small change and no observable
dose-dependency. Because of the lack of inotropic effects by
PP and PYY (3-36), the translocation of ECF was not sig-
NPY Receptor-mediated ANP Release 1031
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(3-36) lack direct atrial inotropic effects. 
What is the physiological significance of PP-induced ANP
release? It has been reported that following ingestion of food
or hypoglycemia, PP is released from pancreatic F islet cells
into circulation to regulate pancreatic and gastric secretion.
We do not know the blood concentration of PP in hypo-
glycemic condition. However, it is possible that PP-induc-
ed ANP release may partly participate the ANP-dependent
lipolysis (27) followed by an increased blood glucose level. 
In conclusion, we suggest that NPY Y2 and Y4 receptors
differently regulate the release of atrial ANP. 
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